Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Ureter Injury Clinical Trial

Official title:

An Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Efficacy, and Physician Satisfaction of Two Different Doses of Bludigo™ (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06054880
• Other study ID #: PVP-22IC04
• Status: Recruiting
• Phase: Phase 4
• Start date: October 12, 2023
• Est. completion date: January 30, 2025

Study information

• Verified date: September 2023
• Source: Prove pharm
• Contact: Michelle Boytim, P.hD.
• Phone: 610-850-7115
• Email: michelle.boytim[@]provepharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo™ (indigotindisulfonate Sodium Injection, USP) 0.8% when used as an aid in the determination of ureteral patency.

Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure, age 18 to 85 years inclusive, will be screened for participation. Screening will occur within 30 days before study drug administration (Day of Surgery). After signing the informed consent, review of inclusion and exclusion criteria will be performed, the collection of concomitant medications, medical history, physical examination, baseline laboratory testing, 12-lead ECG, and vital sign measurements will be completed during the screening visit.

On the day of surgery (Day 1) subjects will be evaluated for eligibility for randomization. Eligible subjects will be stratified by BMI (<30.0 kg/m2or ≥ 30.0 kg/m2) and randomized in a 1:1 ratio to receive a dose of either Bludigo™ high dose (5.0 mL) or Bludigo™ low dose (2.5 mL). Each randomized subject will serve as his/her own control (i.e., intra-patient controlled) by receiving a dose of normal saline prior to receiving the randomized Bludigo™ dose.

All treated subjects will have a follow-up visit 7 to 30 days (± 2 days) after the procedure. A final telephone follow-up call will occur on Day 30 (± 2 days) in subjects who have the follow-up visit before Day 28. Safety assessments will include monitoring of AEs during and post the procedure, clinical laboratory tests, 12-Lead ECG, and vital sign measurements.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 116
• Est. completion date: January 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subjects between = 18 and = 85 years old

• Subjects who signed a written IRB approved, informed consent form

• Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure

Exclusion Criteria:

• Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR <30 mL/min (calculated using the MDRD formula and standardized by using individual's body surface area) or need for dialysis in the near future, or having only 1 kidney

• Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes

• Known history of drug or alcohol abuse within 6 months prior to the time of screening visit

• Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases)

• Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures

• Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

• Subjects with life expectancy < 6 months

• Requirement for concomitant treatment that could bias primary evaluation.

• Subjects who are pregnant or breast-feeding

Related Conditions & MeSH terms

• Ureter Injury

Intervention

Drug:
• Indigotindisulfonate sodium 0.8%
Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Other:
• Saline injection 0.9%
Placebo

Locations

Country	Name	City	State
United States	Albany Medical Center	Albany	New York

Sponsors (1)

Lead Sponsor	Collaborator
Prove pharm

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Paired sample difference (Bludigo™-Saline) in urine jet conspicuity score .	Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows: = No jet observed; = Weak jet, little color contrast; = Color contrast or significant jet flow; = Strong jet flow with good color contrast; = Strong jet flow with striking contrast in color; Paired sample difference (Bludigo™-Saline) in conspicuity score (PSDCS). PSDCS will be calculated for each ureter (left or right) for each subject from each reviewer.	10 minutes post study drug administration
Primary	Responders to Bludigo	Visualization will be measured by a conspicuity scale designed to provide an objective tool applicable to the visualization of the urinary flow from the ureteral orifices when determining ureter patency. The conspicuity of the urine flow from the ureteral orifices is defined using the 5-point conspicuity score as follows: = No jet observed; = Weak jet, little color contrast; = Color contrast or significant jet flow; = Strong jet flow with good color contrast; = Strong jet flow with striking contrast in color; A subject is considered a responder to Bludigo™ if there is >=1 point improvement in the conspicuity score following the Bludigo™- treatment vs the saline treatment and the conspicuity score for the Bludigo™ treatment must be (3, 4, or 5). The responder criteria will be assessed separately for each ureter (left or right) from each reviewer.	10 Minutes post study drug administration
Secondary	Incidence of adverse events and serious adverse events.	Percentage of patients in each treatment group who experience an adverse event post treatment	30 days post study drug administration
Secondary	Changes in clinical safety laboratory values	Proportion of subjects with clinically important changes in clinical safety laboratory tests after treatment	30 days post study drug administration
Secondary	Changes in vital signs post treatment	Proportion of subjects with clinically important changes in vital signs after treatment	30 days post study drug administration
Secondary	Changes in ECG post treatment	Proportion of subjects with clinically important changes in ECGs after treatment	30 days post study drug administration
Secondary	Changes in blood pressure by dose group and BMI (kg/m^2)	Comparison of post treatment changes in blood pressure by dose group and BMI (kg/m^2)	30 days post study drug administration
Secondary	Changes in heart rate by dose group and BMI (kg/m^2)	Comparison of post treatment changes in heart rate by dose group and BMI (kg/m^2)	30 days post study drug administration
Secondary	Changes in pulse oximetry by dose group and BMI (kg/m^2)	Comparison of post treatment changes in pulse oximetry by dose group and BMI (kg/m^2)	30 days post study drug administration
Secondary	Physician Satisfaction	To determine physicians' overall satisfaction with the Bludigo™ treatment by assessing the proportion of surgeons who agree using the 5-point Physician Satisfaction Agreement Scale (PSAS) with the statement: "Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of Bludigo™."; = Strongly Agree; = Agree; = Neither Agree nor Disagree; = Disagree; = Strongly Disagree A surgeon's evaluation is considered satisfactory if the rating is either a 1 (strongly agree) or 2 (agree).	10 Minutes post study drug administration
Secondary	Time to visualization	To describe the time to visualization (TTV) of blue color in the ureteral jets flow following Bludigo™ treatment	10 minutes post study drug administration